Ruxolitinib

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Hand Dermatitis

Conditions

Chronic Hand Dermatitis

Trial Timeline

Jul 11, 2022 → Dec 31, 2024

NCT ID

NCT05293717

About Ruxolitinib

Ruxolitinib is a phase 1/2 stage product being developed by Incyte for Chronic Hand Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05293717. Target conditions include Chronic Hand Dermatitis.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Hand Dermatitis were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03147742	Pre-clinical	Completed	—	—	Graft-versus-host Disease (GVHD)
NCT04355793	Pre-clinical	Completed	—	—	COVID-19
NCT01730755	Pre-clinical	Completed	—	—	Erythrocytosis, Familial, 2
NCT05722912	Pre-clinical	Completed	—	—	Graft-versus-host Disease (GVHD)
NCT07424222	Phase 1	Recruiting	May 1, 2026	Dec 1, 2028	Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
NCT07356245	Phase 2	Recruiting	Feb 1, 2026	Jan 31, 2027	T-cell Lymphoma
NCT07252050	Phase 1/2	Recruiting	Jan 1, 2026	Nov 19, 2029	Sickle Cell Disease
NCT07085039	Phase 2	Recruiting	Dec 18, 2025	Dec 31, 2028	Castleman's Disease (CD)
NCT05293717	Phase 1/2	Completed	Jul 11, 2022	Dec 31, 2024	Chronic Hand Dermatitis
NCT04908280	Phase 2	Completed	May 4, 2022	Mar 4, 2024	Discoid Lupus Erythematosus
NCT04807777	Phase 2	Terminated	Apr 7, 2022	Oct 4, 2023	Advanced Cutaneous Squamous Cell Carcinoma
NCT04644211	Phase 2	Recruiting	Mar 21, 2022	Jul 1, 2034	Essential Thrombocythemia
NCT04354714	Phase 2	Withdrawn	Jun 30, 2020	Dec 31, 2021	COVID-19
NCT03801434	Phase 2	Recruiting	Nov 15, 2019	Dec 30, 2028	BCR-JAK2 Fusion Protein Expression
NCT03722407	Phase 2	Active	Aug 28, 2019	Jun 1, 2026	Chronic Myelomonocytic Leukemia
NCT03674047	Phase 2	Active	Apr 19, 2019	Dec 1, 2025	Other Cancer
NCT03427866	Phase 2	Completed	Aug 28, 2018	May 19, 2025	Myelofibrosis
NCT03153982	Phase 2	Terminated	Jun 8, 2018	Oct 18, 2023	Head and Neck Squamous Cell Carcinoma
NCT01895842	Phase 1	Completed	Feb 1, 2014	Apr 2, 2019	Leukemia
NCT01776723	Phase 1/2	Completed	Feb 20, 2013	May 10, 2022	Myelomonocytic Leukemia

Competing Products

20 competing products in Chronic Hand Dermatitis

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25